Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) headquartered in Cambridge, will host a conference call for the investment community to discuss the 2Q20 financial results on 10th August 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.momentapharma.com
Earnings Expectation
Momenta Pharmaceuticals, Inc. is expected to report second quarter earnings results, before market open, on Monday 10th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.39 per share. Looking ahead, the full year loss are expected at $ 1.62 per share on the revenues of $ 26.47 million.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The companys biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohns disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME.
